Extension

byNordic Acquisition Corporation Announces Extension of Deadline to Complete Business Combination

Retrieved on: 
Monday, March 11, 2024

New York, NY, March 11, 2024 (GLOBE NEWSWIRE) -- byNordic Acquisition Corporation (NASDAQ: BYNO (“BYNO” or the “Company”), a special purpose acquisition company, announced today that the Company has timely deposited into the Company’s trust account (the “Trust Account”), an aggregate of $105,000, in order to extend the period of time the Company has to complete a business combination for an additional one (1) month period, from March 12, 2024 to April 12, 2024 (the “Extension”).

Key Points: 
  • New York, NY, March 11, 2024 (GLOBE NEWSWIRE) -- byNordic Acquisition Corporation (NASDAQ: BYNO (“BYNO” or the “Company”), a special purpose acquisition company, announced today that the Company has timely deposited into the Company’s trust account (the “Trust Account”), an aggregate of $105,000, in order to extend the period of time the Company has to complete a business combination for an additional one (1) month period, from March 12, 2024 to April 12, 2024 (the “Extension”).
  • The Extension is the second of up to six (6) one-month extensions permitted under the August 10, 2023 amendment to the Company’s Amended and Restated Certificate of Incorporation that allows the Company’s board of directors, in its sole discretion and without another stockholder vote, to elect to extend the termination date by one additional month each time up until August 12, 2024, or the closing of the Company’s initial business combination.

ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®

Retrieved on: 
Monday, March 11, 2024

RAMSEY, N.J. and BOCA RATON, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced the United States Food and Drug Administration’s (“FDA”) approval for its supplemental Biologics License Applications (BLAs) for both ASCENIV and BIVIGAM to extend the approved 4-week room temperature (25°C) storage conditions during the first 24 months of shelf life, to allow for a 4-week room temperature storage at any time during the entire 36-month approved shelf life. The room temperature approval applies to all existing ASCENIV and BIVIGAM lots currently in the commercial supply chain as well as to future production of ASCENIV and BIVIGAM.

Key Points: 
  • Approval of Extended Ambient Storage Conditions for ASCENIV & BIVIGAM is Immediately Effective and Now Commercially Available to U.S. Healthcare Providers
    RAMSEY, N.J. and BOCA RATON, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced the United States Food and Drug Administration’s (“FDA”) approval for its supplemental Biologics License Applications (BLAs) for both ASCENIV and BIVIGAM to extend the approved 4-week room temperature (25°C) storage conditions during the first 24 months of shelf life, to allow for a 4-week room temperature storage at any time during the entire 36-month approved shelf life.
  • The room temperature approval applies to all existing ASCENIV and BIVIGAM lots currently in the commercial supply chain as well as to future production of ASCENIV and BIVIGAM.
  • “With the FDA-approved extension of room temperature storage conditions, the Company expects to reach more customers who were previously inaccessible due to limited refrigeration space and cold chain capacity constraints,” said Adam Grossman, President and Chief Executive Officer of ADMA.
  • “We believe that this added storage flexibility for both ASCENIV and BIVIGAM will meaningfully enhance our products’ market offerings, enabling more versatile utilization and better inventory management for providers.”
    The newly approved extension of room temperature storage conditions for both ASCENIV and BIVIGAM is immediately effective, and both products are commercially available to U.S. healthcare providers and patients.

Kernel Group Holdings, Inc. Extends Period to Consummate Initial Business Combination

Retrieved on: 
Tuesday, March 5, 2024

New York, March 05, 2024 (GLOBE NEWSWIRE) -- Kernel Group Holdings, Inc. (NASDAQ: KRNLU, KRNL, KRNLW) (“KRNL” or the “Company”), a special purpose acquisition company, announced today that it has elected to extend the period of time it has to consummate its initial business combination by one month from March 5, 2024 to April 5, 2024 (the “Extension”).

Key Points: 
  • New York, March 05, 2024 (GLOBE NEWSWIRE) -- Kernel Group Holdings, Inc. (NASDAQ: KRNLU, KRNL, KRNLW) (“KRNL” or the “Company”), a special purpose acquisition company, announced today that it has elected to extend the period of time it has to consummate its initial business combination by one month from March 5, 2024 to April 5, 2024 (the “Extension”).
  • The Extension is the second of six-monthly extensions permitted under the Company’s governing documents.
  • Certain statements in this press release are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby.
  • These statements are based on the current beliefs and expectations of the Company’s management, including the Company’s ability to consummate its initial business combination and are subject to significant risks and uncertainties.

Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to April 3, 2024

Retrieved on: 
Monday, March 4, 2024

MIAMI, March 04, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”), a special purpose acquisition company, announced today that on March 1, 2024, its sponsor, Vision Sensing, LLC, deposited $60,000 into the Company’s trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from March 3, 2024, to April 3, 2024 (the “Extension”).

Key Points: 
  • MIAMI, March 04, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”), a special purpose acquisition company, announced today that on March 1, 2024, its sponsor, Vision Sensing, LLC, deposited $60,000 into the Company’s trust account, which is the sum that the Company must pay to extend the date by which the Company must consummate its initial business combination from March 3, 2024, to April 3, 2024 (the “Extension”).
  • The Company has issued to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $60,000 as consideration for the funding.
  • This is the fifth of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on October 25, 2023.
  • The Extension provides the Company with additional time to complete its initial business combination (the “Business Combination”) with Mediforum Co. Ltd., a Korean company (“Mediforum”), pursuant to a merger agreement dated January 12, 2024 (as it may be amended and/or restated from time to time, the “Merger Agreement”).

Ross Acquisition Corp II Announces Meeting for Shareholders to Extend Date for Business Combination

Retrieved on: 
Thursday, February 29, 2024

The Extension Amendment Proposal is described in more detail in the Definitive Proxy Statement.

Key Points: 
  • The Extension Amendment Proposal is described in more detail in the Definitive Proxy Statement.
  • Beneficial owners of Public Shares held in “street name,” however, will not need to take any action in order to receive the redemption amount.
  • The proceeds of the Trust Account will be held in a non-interest bearing account while awaiting disbursement.
  • The Company’s initial shareholders have waived their redemption rights with respect to the outstanding Class B ordinary shares issued prior to the Company’s initial public offering.

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to April 3, 2024

Retrieved on: 
Wednesday, February 28, 2024

MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock Transfer & Trust Company that it intends to extend the date by which the Company must consummate its initial business combination from March 3, 2024, to April 3, 2024, and that its sponsor, Vision Sensing, LLC, intends to deposit into the Company’s trust account an aggregate of $60,000 by March 3, 2024 (the “Extension”).

Key Points: 
  • MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock Transfer & Trust Company that it intends to extend the date by which the Company must consummate its initial business combination from March 3, 2024, to April 3, 2024, and that its sponsor, Vision Sensing, LLC, intends to deposit into the Company’s trust account an aggregate of $60,000 by March 3, 2024 (the “Extension”).
  • In connection with the Extension, the Company intends to issue to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $60,000 as consideration for the funding.
  • This will be the fourth of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on October 25, 2023.
  • The Extension provides the Company with additional time to complete its initial business combination (the “Business Combination”) with Mediforum Co. Ltd., a Korean company (“Mediforum”), pursuant to a merger agreement dated January 12, 2024 (as it may be amended and/or restated from time to time, the “Merger Agreement”).

Every Cure to Receive $48.3M from ARPA-H to Develop AI-Driven Platform to Revolutionize Future of Drug Development and Repurposing

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Every Cure, a nonprofit on a mission to save lives by repurposing existing medicines, announced today significant funding from the Advanced Research Projects Agency for Health (ARPA-H). The three-year, $48.3 million contract was unveiled at the White House this evening and represents a substantial federal investment in drug repurposing. It will accelerate Every Cure's mission to unlock the full potential of existing drugs to treat more diseases through the development of an AI-powered platform, called ML/AI-enabled Therapeutic Repurposing In eXtended uses (MATRIX).

Key Points: 
  • The three-year, $48.3 million contract was unveiled at the White House this evening and represents a substantial federal investment in drug repurposing.
  • "I'm alive and in remission from my rare disease thanks to a repurposed drug that I discovered.
  • "Through Every Cure, we are working tirelessly to unlock the full potential of FDA-approved drugs to treat many more diseases.
  • The ARPA-H funding will enable Every Cure to:
    Develop an open-source drug repurposing database.

Kingswood Acquisition Corp. Makes Announcements Regarding Two Special Meetings of Stockholders

Retrieved on: 
Tuesday, February 20, 2024

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Kingswood Acquisition Corp. (OTC: KWAC) (the "Company") made announcements today concerning its two upcoming special meetings of its stockholders.

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Kingswood Acquisition Corp. (OTC: KWAC) (the "Company") made announcements today concerning its two upcoming special meetings of its stockholders.
  • Separately, the Company announced today that the special meeting of the Company's stockholders to vote upon the Company's initial business combination and related matters (the "Business Combination Meeting"), which was originally scheduled for Thursday, February 22, 2024, at 12:00 p.m., Eastern Time, is being postponed to Wednesday, March 6, 2024, at 11:00 a.m., Eastern Time.
  • The Business Combination Meeting will still be held via live webcast at www.cstproxy.com/kingswoodacquisition/2024 and there has been no change to the record date for, the purpose of or any of the proposals to be acted upon at the Business Combination Meeting.
  • Stockholders who have questions or need assistance in connection with the either the Extension Meeting or Business Combination Meeting should contact the Company's proxy solicitor, Morrow Sodali LLC, at 333 Ludlow Street, 5th Floor, South Tower, Stamford, Connecticut 06902, [email protected] .

Tennessee Oncology Launches Rural Telehealth Program to Bridge Digital Divide for Middle Tennessee Cancer Patients

Retrieved on: 
Tuesday, February 20, 2024

To kick off the program, Tennessee Oncology is recruiting Middle Tennessee cancer patients, caregivers, survivors, and patient advocates to participate in the program's design as part of Community Advisory Boards (CABs).

Key Points: 
  • To kick off the program, Tennessee Oncology is recruiting Middle Tennessee cancer patients, caregivers, survivors, and patient advocates to participate in the program's design as part of Community Advisory Boards (CABs).
  • During the Covid-19 pandemic when Tennessee Oncology rapidly deployed telehealth services, patient participation in palliative care, psychology, and integrative oncology grew.
  • In 2022, only 1.5 percent of breast cancer patients and 2.7 percent of prostate cancer patients accessed palliative care in rural and underserved Tennessee counties.
  • "NEST was born from what we learned using telehealth to connect our patients with cancer care services during the pandemic," said Natalie Dickson, MD, President and Chief Strategy Officer, Tennessee Oncology.

Arisz Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Retrieved on: 
Friday, February 16, 2024

The Extension is the first of up to nine (9) one-month extensions permitted under the February 5, 2024 amendment to the Amended and Restated Certificate of Incorporation of Arisz Acquisition Corp.

Key Points: 
  • The Extension is the first of up to nine (9) one-month extensions permitted under the February 5, 2024 amendment to the Amended and Restated Certificate of Incorporation of Arisz Acquisition Corp.
  • The Extension provides Arisz with additional time to complete its proposed business combination with Finfront Holding Company (“BitFuFu”).
  • Statements that are not historical facts, including statements about the pending transactions described above, and the parties’ perspectives and expectations, are forward-looking statements.
  • Stockholders will also be able to obtain a copy of the Registration Statement and proxy statement without charge from Arisz.